Humana Inc. Files 8-K for Regulation FD Disclosure

TL;DR

Humana filed an 8-K for a Reg FD disclosure, no major news.

AI Summary

Humana Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or new material events beyond the disclosure itself.

Why It Matters

This filing indicates Humana Inc. is adhering to disclosure regulations, ensuring timely and fair information dissemination to the public.

Risk Assessment

Risk Level: low — The filing is a standard regulatory disclosure and does not indicate any immediate financial or operational risks.

Key Players & Entities

• HUMANA INC (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Louisville (location) — Principal executive offices city
• Kentucky (location) — Principal executive offices state

FAQ

Key Financial Figures

• $13.93 — reaffirm its guidance of approximately $13.93 in diluted earnings per common share ("
• $16.00 — r common share ("EPS") or approximately $16.00 in adjusted earnings per common share (

Filing Documents

• hum-20240603.htm (8-K) — 32KB
• 0000049071-24-000027.txt ( ) — 153KB
• hum-20240603.xsd (EX-101.SCH) — 2KB
• hum-20240603_lab.xml (EX-101.LAB) — 21KB
• hum-20240603_pre.xml (EX-101.PRE) — 12KB
• hum-20240603_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Members of Humana Inc.'s (the "Company") senior management team are scheduled to meet with investors and analysts between June 3, 2024 and June 28, 2024. During these meetings, the Company intends to reaffirm its guidance of approximately $13.93 in diluted earnings per common share ("EPS") or approximately $16.00 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2024 ("FY 2024"). This guidance is consistent with the guidance issued in Humana's press release dated April 24, 2024. The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles ("GAAP"). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company's core operating performance over time. Consequently, management uses Adjusted EPS as a consistent and uniform indicator of the Company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows: Diluted earnings per common share FY 2024 Guidance GAAP approximately $13.93 Amortization of identifiable intangibles 0.49 Put/call valuation adjustments associated with Company's non-consolidating minority interest investments 1.08 Impact of exit of employer group commercial medical products business 0.90 Value creation initiatives 0.24 Cumulative net tax impact of non-GAAP adjustments (0.64) Adjusted (non-GAAP) – FY 2024 projected approximately $16.00 Cautionary Statement This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. HUMANA INC. BY: /s/ John-Paul W. Felter John-Paul W. Felter Senior Vice President, Chief Accounting Officer & Controller (Principal Accounting Officer) Dated: June 3, 2024

View Full Filing

View this 8-K filing on SEC EDGAR